Aron Jaffe

SVP @ SVP Head of Research @chromamedicine;EIR @ThirdRockV;Reg Med, uBiome group leader/Resp DA co-lead @NovartisScience. Opinions mine

[Aron Jaffe @jaffeab]

Our work describing the development of a potent epigenetic editor targeting human #PCSK9 for durable reduction of LDL-C is out in @NatureMedicine today!
Cc: @chromamedicine @nchromabio
1/9

https://t.co/cnelNtMT0W

[Aron Jaffe @jaffeab]

Amazing news for chronic HBV patients: bepirovirsen B-Well Ph3 published in @NEJM & presented at #EASLCongress: 19% functional cure (HBsAg loss + undetectable DNA ≥24 wks post-treatment) vs 0% placebo. This is the new bar. Congrats to @GSK @ionispharma https://t.co/jSd2SZZ4V8

[Aron Jaffe @jaffeab]

Happy birthday to two of my favorite people in the world - Ralph DeBerardinis (@rjdlab), who turns 50 today, and Alan Hall, who would have been 68. In addition to sharing a birthday, Ralph and Alan have quite a bit in common (thread)

https://t.co/zTnJTOzbBk

[Aron Jaffe @jaffeab]

👇💯

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Thanks for sharing view, @jrkelly!

This is a polarizing issue, as you know.

I, for one, do not support breaking access to China-based manufacturing or innovation. It would harm patients, and that MUST remain our Northstar.

On the other hand, I think China’s recent advances must be a “Sputnik moment” for the U.S.. For starters, we should stop and reverse the self-inflicted damage created by certain Administration policies, including reduced NIH funding, FDA instability, drug price controls, H1B visa restrictions, and an anti-Vax/anti-science agenda. 

Then, we should find smart ways to increase our global competitiveness, including reducing barriers to efficient clinical evidence generation, creating incentives for U.S. clinical trial and manufacturing, and reforming PBMs/340B to ensure reward for the innovator, not the middleman.

We can win this competitive race with American ingenuity and resolve, not with walls and barriers!

[Aron Jaffe @jaffeab]

A couple of sliders from a vending machine just before a flight.

What could go wrong?

[Aron Jaffe @jaffeab]

Very good news from @REGENXBIO and for Duchenne patients

Presentation tomorrow @ASGCTherapy #ASGCT2026

Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission https://t.co/rmjWjxWM64 via @statnews

[Aron Jaffe @jaffeab]

Congrats @bloodgenes !

[Vijay Sankaran @bloodgenes]

🚨 Excited to share a new paper in Cell! Human genetics led us to HOTSCRAMBL, a HOXA-locus lncRNA that regulates 🩸#stemcell self-renewal and HOXA9 splicing, with implications for AML.

Amazing work by @lvchosen1 with @silvirouskin, @Armstrong_dfci, and many more!

https://t.co/Kralk3tmzg

[Aron Jaffe @jaffeab]

Congratulations to the now Twitterless/Xless Ralph DeBerardinis on being elected to @theNASciences!!!

[Children’s Research Institute at UT Southwestern @CRI_UTSW]

🌟From the desk of @SJMorrison_: It's a great day for CRI, which now has 2 @theNASciences members. Congratulations to Ralph DeBerardinis, M.D., Ph.D., and his laboratory on this recognition for the quality and impact of their work! #relentlessdiscovery
https://t.co/drqKPSLL3z

[Aron Jaffe @jaffeab]

Congrats @IOB_Roska and all the awardees!

[IOB.ch @IOB_ch]

👁‍🗨We turn science into sight.
Congratulations to our Director @IOB_Roska on receiving the 2026 Future Vision Award alongside Connie Cepko & Daniel Ting. A recognition of long-term research now reaching patients.
🎬Watch the short movies: https://t.co/mbWgbGdpbN
#Vision #Retina #Ophthalmology #Blindness #Neuroscience #ScienceInnovation #VisionRestoration #EyeHealth #BiomedicalResearch

[Aron Jaffe @jaffeab]

Congrats to all involved in getting this important medicine to patients - teams @Regeneron & DecibelTx, Joe Burns, Adam Palermo, Jonathan Whitton, @jkeilty, Laurence Reid, many others…

& big props to @Regeneron for providing Otarmeni for free in the US

https://t.co/Beon2jHvlt

[Aron Jaffe @jaffeab]

Couldn’t agree more!

As my wife and I tell our two kids - actions have consequences!

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

“We are losing scientists, we’re losing our IP, we’re losing physicians, we’re losing the best researchers, and we’re going to lose our biosecurity,” Kennedy said.

Well, maybe we should STOP all the self-inflicted damage by: funding academic research, attracting best scientists from all over the world with H1B visa program, supporting a strong, consistent FDA without political influence, supporting our public health infrastructure, and supporting scientists!

[Aron Jaffe @jaffeab]

Best of luck to all!
#bostonmarathon

[Boston Marathon Pro @Boston26_2_Pro]

We are ready for you! See you at the finish! ⁦@bostonmarathon⁩

[Breakthrough @brkthroughprize]

Congratulations to Jean Bennett, Katherine A. High and Albert Maguire, winners of the 2026 Breakthrough Prize in Life Sciences, for developing a therapy for inherited retinal degeneration that became the first FDA-approved gene therapy for a genetic disease. https://t.co/awmRtAX5vT
@Penn @ChildrensPhila @RockefellerUniv

[Anirban Maitra @Aiims1742]

That Phase 3 overall survival data is in second line #PancreaticCancer which makes the numbers even more astounding. I cannot recall any other example in pancreatic cancer when OS in a Phase 3 trial basically doubled over existing standard of care.
https://t.co/89kVHEmSMh

[Aron Jaffe @jaffeab]

👏👏👏

[Adam Feuerstein ✡️ @adamfeuerstein]

Finally, best news of the morning (and something you didn't expect so soon)...

Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer.

Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7 months.

OS Hazard ratio 0.40

[Matthew Herper @matthewherper]

A decade ago, these drugs tore apart the FDA. Today, they might be some patients’ best hope 

Another wonderful piece from @Jasonmmast

https://t.co/zOvLrdAPKi via @statnews

[Aron Jaffe @jaffeab]

Great piece from @ercgrn

I <3 genetics

Huntington’s Disease and The Triad of Therapeutic Conviction https://t.co/tWMVT8ktFe

[Veera Rajagopal  @doctorveera]

Resharing this piece I wrote last year on human genetics and drug discovery.

India’s genetic diversity is an underexplored asset, one that can fundamentally reshape how we discover new medicines.

This is exactly the direction we’re building towards 🇮🇳

https://t.co/0yh2gmaUaP

[Aron Jaffe @jaffeab]

India’s Boundless Biotech Potential

That potential starts with human genetics!

⁦⁦@doctorveera⁩ https://t.co/SylLLFNLbW

[Aron Jaffe @jaffeab]

Congrats @davidjglassMD!

[David J Glass MD @davidjglassMD]

Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity

https://t.co/bl25n6ijJv

[Aron Jaffe @jaffeab]

Go @philandrew_IL9 !!!